文献速递肝胆胰外科围术期管理与 ERAS

胰腺导管腺癌新辅助化疗后手术决策:预后预测模型

Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy.
PubMed 文献 · Ann Surg · 2021-04-09

基于单中心2007–2018年581例接受术前化疗后胰腺切除的PDAC患者数据,建立预测OS和RFS的Cox比例风险模型及交互式预后工具。中位OS为29.5个月,中位RFS为16.6个月。OS和RFS与化疗药物类型及术前化疗周期数相关,模型经迭代bootstrap和随机队列拆分验证,OS和RFS的C指数分别为0.68和0.65。

要点

  • 术前化疗类型和周期数影响PDAC切除后OS和RFS
  • 肿瘤分级、病理缓解、淋巴结状态和辅助化疗也纳入预后模型
  • 交互式工具可估算OS、RFS及部位特异性复发率,辅助手术决策讨论

核心结论

  • 开发了可动态估算PDAC术前化疗后切除患者OS、RFS和部位特异性复发率的决策工具。
  • 该预后工具有助于与患者讨论手术切除的获益。

研究设计与样本

  • 单中心高容量机构2007–2018年前瞻性数据库,纳入581例术前接受化疗后行胰腺切除的PDAC患者。
  • 采用Cox比例风险回归建模,迭代bootstrap和随机队列拆分验证。

主要发现

  • 多变量分析显示OS和RFS与化疗药物类型及术前化疗周期数相关。
  • 肿瘤分级、病理缓解、淋巴结状态和辅助化疗也是生存模型的 contributing 因素。
  • 最终OS和RFS模型的C指数分别为0.68和0.65,校准良好。

临床怎么用

  • 围术期可使用该交互式工具估算个体化OS、RFS和复发风险。
  • 结合化疗类型、周期数、肿瘤分级、病理缓解、淋巴结状态和辅助化疗进行预后讨论。

局限性

  • 单中心高容量机构数据,外推性需进一步验证。
  • 回顾性数据收集可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a predictive model of oncologic outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) undergoing resection after neoadjuvant or induction chemotherapy use. BACKGROUND: Early recurrence following surgical resection for PDAC is common. The use of neoadjuvant chemotherapy prior to resection may increase the likelihood of long-term systemic disease control. Accurately characterizing an individual's likely oncologic outcome in the perioperative setting remains challenging. METHODS: Data from patients with PDAC who received chemotherapy prior to pancreatectomy at a single high-volume institution between 2007 and 2018 were captured in a prospectively collected database. Core clinicopathologic data were reviewed for accuracy and survival data were abstracted from the electronic medical record and national databases. Cox-proportional regressions were used to model outcomes and develop an interactive prognostic tool for clinical decision-making. RESULTS: A total of 581 patients were included with a median overall survival (OS) and recurrence-free survival (RFS) of 29.5 (26.5-32.5) and 16.6 (15.8-17.5) months, respectively. Multivariable analysis demonstrates OS and RFS were associated with type of chemotherapeutic used andthe number of chemotherapy cycles received preoperatively. Additional factors contributing to survival models included: tumor grade, histopathologic response to therapy, nodal status, and administration of adjuvant chemotherapy. The models were validated using an iterative bootstrap method and with randomized cohort splitting. The models were well calibrated with concordance indices of 0.68 and 0.65 for the final OS and RFS models, respectively. CONCLUSION: We developed an intuitive and dynamic decision-making tool that can be useful in estimating OS, RFS, and location-specific disease recurrence rates. This prognostic tool may add value to patient care in discussing the benefits associated with surgical resection for PDAC.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Habib JR, Kinny-Köster B, Bou-Samra P, et al. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. Ann Surg. 2021. PMID: 33843794. doi:10.1097/SLA.0000000000004915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。